Adjuvant IL-2 offers survival benefit in metastatic RCC

Article

Orlando, FL-In patients with metastatic renal cell carcinoma, adjuvant interleukin-2 (IL-2) after cytoreductive nephrectomy appears to offer a superior survival benefit over nephrectomy followed by interferon alpha-2b, according to a report presented here at the American Society of Clinical Oncology annual meeting.

Related Videos
Bree Duncan, RN, BSN, answers a question during a Zoom video interview
Orange pill bottle with loose pills spilling out | Image Credit: © Antonio Rodriguez - stock.adobe.com
A panel of 5 experts on prostate cancer
A panel of 5 experts on prostate cancer
3d rendered illustration of bladder cancer | Image Credit: © SciePro - stock.adobe.com
Heather L. Huelster, MD, answers a question during a Zoom video interview
3d rendered illustration of kidney cancer | Image Credit: © SciePro - stock.adobe.com
Related Content
© 2023 MJH Life Sciences

All rights reserved.